US › Healthcare

ImageneBio, Inc. (IMA)

US · Healthcare · Biotechnology

$5.71+1.24%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-10.6M
Profit YoY
-23.2%
EPS
$-0.72
EPS estimate
$-0.90

EPS came in at -0.72 against a street estimate of -0.90 — a beat of 20.0%.

Key statistics

Market cap
$63.0M
Forward P/E
0.0
P/B
0.51
Book value
$10.93
EPS (TTM)
$-4.78
52-week high
$16.50
52-week low
$3.94
50-day MA
$5.76
200-day MA
$6.37

Analyst view

with an average price target of $13.00.

Shareholding

Insiders
12.62%
Institutions
48.16%

Largest institutional holders

FundStake
Bvf Inc9.84%
Blue Owl Capital Holdings LP8.51%
Cable Car Capital LLC6.69%
Omega Fund Management LLC4.04%
Orbimed Advisors, LLC3.36%
RTW INVESTMENTS, LLC2.97%
Vanguard Capital Management, LLC2.88%
BML Capital Management LLC1.78%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for ImageneBio, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.